Microparticle-associated tissue factor activity: A link between cancer and thrombosis?

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 3, 2007, Pages 520-527

  Tesselaar, M E T ^a   Romijn, F P H T M ^a   Van Der Linden, I K ^a   Prins, F A ^a   Bertina, R M ^a   Osanto, S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast neoplasms; Nanoparticles; Neoplasms; Pancreatic neoplasms; Tissue factor; Venous thrombosis

Indexed keywords

MUCIN 1; NANOPARTICLE; THROMBOPLASTIN; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE DETERMINATION; AGED; ARTICLE; BREAST ADENOCARCINOMA; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PANCREAS ADENOCARCINOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; THROMBOGENESIS; VENOUS THROMBOEMBOLISM; BLOOD; BLOOD CLOTTING; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; CYTOPLASM VESICLE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICAL MODEL; THROMBOEMBOLISM; TIME; VEIN THROMBOSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTIGENS, NEOPLASM; BLOOD COAGULATION; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CYTOPLASMIC VESICLES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MUCINS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPLASTIN; TIME FACTORS; VENOUS THROMBOSIS;

EID: 34247606502     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02369.x     Document Type: Article

References (39)

1. Trousseau A. In Clinique Medicale de l'Hotel-dieu de Paris. Phlegmasia Alba Dolens. Paris: JB Balliere et Fils, 1865: 654-715.
2. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
3. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: Results of a record linkage study. J Thromb Haemost 2006; 4: 529-35.
4. Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 1975; 6: 433-58.
5. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: A cohort study of 202 patients. Eur J Cancer 2006; 42: 410-4.
6. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-91.
7. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
8. Rickles FR, Levine MN, Dvorak HF. Abnormalities of hemostasis in malignant disease. In: Colman W, Hirsch J, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia: Lippincot Williams and Wilkins, 2001: 1131-52.
9. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost 2005; 31: 104-10.
10. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
11. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
12. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.
13. Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-4.
14. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br J Cancer 2000; 83: 164-70.
15. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996; 56: 5063-70.
16. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995; 346: 1004-5.
17. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
18. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: Two sides of the coin. Physiology (Bethesda) 2005; 20: 22-7.
19. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-64.
20. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-46.
21. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-52.
22. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
23. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, Sampol J, Dignat-George F. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-5.
24. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004; 2: 2065-7.
25. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-41.
26. Tesselaar MET, Romijn FPHTM, van der Linden IK, Prins F, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: A link between cancer and thrombosis? Blood 2005; 106: 260a.
27. VanWijk MJ, Svedas E, Boer K, Nieuwland R, VanBavel E, Kublickiene KR. Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002; 187: 1686-93.
28. Bom VJ, van Hinsbergh VW, Reinalda-Poot HH, Mohanlal RW, Bertina RM. Extrinsic activation of human coagulation factors IX and X on the endothelial surface. Thromb Haemost 1991; 66: 283-91.
29. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870-5.
30. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
31. Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004; 15: 521-38.
32. Rehemtulla A, Ruf W, Edgington TS. The integrity of the cysteine 186-cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem 1991; 266: 10294-9.
33. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
34. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105: 2764-70.
35. Jesty J, Beltrami E. Positive-feedback mechanisms of coagulation. Their role in threshold regulation. Arterioscler Thromb Vasc Biol 2005; 25: 2463-9.
36. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian Jr HH, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 1020-5.
37. Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
38. Osterud B. The role of platelets in decrypting monocyte tissue factor. Semin Hematol 2001; 38: 2-5.
39. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003; 112: 853-62.